LENZ Therapeutics, Inc./$LENZ
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About LENZ Therapeutics, Inc.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.
Ticker
$LENZ
Sector
Primary listing
Industry
Pharmaceuticals
Headquarters
Employees
-
ISIN
US52635N1037
Website
LENZ Metrics
BasicAdvanced
$845M
-
-$1.77
-
-
Price and volume
Market cap
$845M
52-week high
$33.42
52-week low
$16.54
Average daily volume
226K
Financial strength
Current ratio
23.09
Quick ratio
22.637
Long term debt to equity
0.351
Total debt to equity
0.616
Profitability
EBITDA (TTM)
-59.364
Effective tax rate (TTM)
-0.00%
Management effectiveness
Return on assets (TTM)
-17.75%
Return on equity (TTM)
-24.47%
Valuation
Price to book
4.31
Price to tangible book (TTM)
4.31
Price to free cash flow (TTM)
-15.559
Free cash flow yield (TTM)
-6.43%
Free cash flow per share (TTM)
-193.01%
Growth
Earnings per share change (TTM)
-93.66%
Bulls say / Bears say
LENZ Therapeutics' lead product, LNZ100, achieved all primary and secondary endpoints in the Phase 3 CLARITY study for presbyopia treatment, indicating strong potential for FDA approval and market success. (stocktitan.net)
Analysts have given LENZ Therapeutics a consensus 'Buy' rating, with an average 12-month price target of $35.40, reflecting confidence in the company's growth prospects. (marketbeat.com)
LENZ Therapeutics has entered into an exclusive license and commercialization agreement with Lotus Pharmaceutical for LNZ100 in the Republic of Korea and Southeast Asia, expanding its market reach. (wallstreetzen.com)
Renaissance Technologies LLC reduced its holdings in LENZ Therapeutics by 48.5% during the fourth quarter, which may indicate decreased confidence from institutional investors. (americanbankingnews.com)
LENZ Therapeutics reported an operating cash flow of -$73.79 million as of June 30, 2024, highlighting significant cash burn that could impact financial stability. (fintel.io)
The company's return on equity is forecasted to be -83.7% in three years, suggesting potential challenges in achieving profitability. (simplywall.st)
Data summarised monthly by Lightyear AI. Last updated on 7 Jun 2025.
LENZ News
AllArticlesVideos
LENZ Therapeutics and Lotus Pharmaceutical Announce Exclusive License and Commercialization Agreement for LNZ100 in the Republic of Korea and Southeast Asia
GlobeNewsWire·1 month ago
LENZ Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
GlobeNewsWire·1 month ago
LENZ Therapeutics to Participate in Upcoming BofA Securities 2025 Health Care Conference
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for LENZ Therapeutics, Inc. stock?
LENZ Therapeutics, Inc. (LENZ) has a market cap of $845M as of June 20, 2025.
What is the P/E ratio for LENZ Therapeutics, Inc. stock?
The price to earnings (P/E) ratio for LENZ Therapeutics, Inc. (LENZ) stock is 0 as of June 20, 2025.
Does LENZ Therapeutics, Inc. stock pay dividends?
No, LENZ Therapeutics, Inc. (LENZ) stock does not pay dividends to its shareholders as of June 20, 2025.
When is the next LENZ Therapeutics, Inc. dividend payment date?
LENZ Therapeutics, Inc. (LENZ) stock does not pay dividends to its shareholders.
What is the beta indicator for LENZ Therapeutics, Inc.?
LENZ Therapeutics, Inc. (LENZ) does not currently have a Beta indicator.